Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Quality Compliance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability at Santen
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2018
IR News
2018 IR News
RSS
IR News
11.27.2018
Santen and Ube Industries Announce Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in Japan
11.22.2018
Corporate Governance Report
11.07.2018
Santen Reports the 2nd Quarter Fiscal 2018 Consolidated Performance
09.25.2018
Santen Donates to the 2018 Hokkaido Eastern Iburi Earthquake Relief Efforts in Japan
09.25.2018
Santen Announces Drug Discovery and Development Agreement with PeptiDream
09.21.2018
Santen Files for Manufacturing and Marketing Approval of Anti-Allergy Ophthalmic Drug Candidate DE-114A (JAN: Epinastine Hydrochloride)
09.21.2018
Santen and Ube Industries Announce Receipt of Manufacturing and Marketing Approval for Glaucoma and Ocular Hypertension Treatment EYBELIS in Japan
09.13.2018
Personnel Changes of Corporate Officer
09.12.2018
Personnel Changes of Representative Director of the Board
08.01.2018
Santen Reports the 1st Quarter Fiscal 2018 Consolidated Performance
07.26.2018
Notice on Completion of Payment for Issuance of New Shares Under Restricted Stock-linked Remuneration Program
07.17.2018
Santen Donates to Japan Flood and Landslide Relief Efforts
07.10.2018
Santen Receives Marketing Authorisation from the European Commission for DE-076C (Verkazia) as an Orphan Medicinal Product
07.10.2018
Corporate Governance Report
06.26.2018
Notice on the Issuance of New Shares Under Restricted Stock-Linked Remuneration Program
06.04.2018
Santen Announces Medium-Term Plan (MTP2020)
05.09.2018
Santen Reports Fiscal 2017 Consolidated Performance
05.09.2018
Notice of Board of Director and Corporate Auditor Nominations
05.09.2018
Notice on the Introduction of a New Stock-Linked Remuneration Program and Change to Director Remuneration
03.14.2018
Notice of Corporate Officer Appointments
02.23.2018
Santen to Conduct a Public Awareness Campaign for Glaucoma During World Glaucoma Week March 11 - 17
02.20.2018
Santen Announces Appointment of New President
02.06.2018
Santen Reports the 3rd Quarter Fiscal 2017 Consolidated Performance
News Archive
